Table 2.

Baseline characteristics

FactorAll Patients, n=70C1 Esterase Inhibitor, n=35Placebo, n=35
Recipient characteristics
 Age, yr, mean (SD)58 (10)58 (8)58 (11)
 Men (%)42 (60)20 (57)22 (63)
 Diabetes mellitus (%)41 (59)21 (60)20 (57)
 Black (%)8 (11)4 (11)4 (11)
Donor characteristics
 Age, yr, mean (SD)47 (14)49 (12)46 (16)
 Creatinine, mg/dl, mean (SD)1.8 (1.7)1.8 (1.4)1.8 (1.9)
 Donor after Cardiac Death (%)23 (33)11 (31)12 (34)
 KDPI, mean (SD)66 (24)68 (22)65 (25)
 KDPI≥85% (%)21 (30)10 (29)11 (31)
Transplant characteristics
 Cold ischemia, h, mean (SD)19 (6)18 (5)20 (6)
Immunologic time characteristics
 Presence of anti-HLA DSA (%)5 (7)3 (9)2 (6)
 Immunodominant class I3 (4)2 (6)1 (3)
 Immunodominant class II2 (3)1 (3)1 (3)
 DSA MFI, mean (SD)5750 (1425)5000 (1250)6875 (884)
 Positive crossmatch (%)2 (3)1 (3)1 (3)
Antibody induction
 Antithymocyte globulin (%)53 (76)25 (71)28 (80)
 Alemtuzumab (%)17 (24)10 (29)7 (20)
  • KDPI, kidney donor profile index; DSA, donor-specific antibody; MFI, mean fluorescence intensity.